CareDx, Inc (NASDAQ:CDNA) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 15.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 448,113 shares of the company's stock after buying an additional 60,050 shares during the period. Nuveen Asset Management LLC owned about 0.84% of CareDx worth $9,594,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Sterling Capital Management LLC raised its stake in CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after buying an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of CareDx by 553.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares in the last quarter. Plato Investment Management Ltd increased its holdings in shares of CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after acquiring an additional 1,370 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in shares of CareDx by 41.5% during the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after acquiring an additional 2,742 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in CareDx in the fourth quarter valued at approximately $208,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright reissued a "neutral" rating and issued a $25.00 target price on shares of CareDx in a report on Monday, May 5th. The Goldman Sachs Group cut their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Finally, Wall Street Zen cut CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.33.

CareDx Stock Performance

CareDx stock traded up $0.38 during midday trading on Friday, reaching $16.94. The stock had a trading volume of 1,184,778 shares, compared to its average volume of 898,143. The stock's 50-day simple moving average is $17.27 and its 200 day simple moving average is $20.53. CareDx, Inc has a twelve month low of $12.90 and a twelve month high of $34.84. The stock has a market capitalization of $943.24 million, a PE ratio of -6.27 and a beta of 2.27.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period in the previous year, the firm earned ($0.03) earnings per share. CareDx's revenue for the quarter was up 17.6% on a year-over-year basis. Equities analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Insider Activity at CareDx

In other news, Director Peter Maag sold 13,281 shares of CareDx stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the sale, the director now directly owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. The trade was a 4.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christine Cournoyer sold 16,700 shares of CareDx stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the sale, the director now owns 37,045 shares in the company, valued at $523,445.85. This represents a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 89,382 shares of company stock worth $1,458,009. 4.90% of the stock is currently owned by company insiders.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.